No abstract

Objective One of the main medical treatment options for monosymptomatic nocturnal enuresis (MNE) is the vasopressin analogue desmopressin. But not all children respond to desmopressin treatment, and no reliable treatment predictor has yet been established. We hypothesize that plasma copeptin, a surrogate marker for vasopressin, can be used to predict treatment response to desmopressin in children with monosymptomatic nocturnal enuresis. Design/Methods In this prospective observational study, we included 28 children with MNE. At baseline, we assessed number of wet nights, morning and evening plasma copeptin and plasma sodium and started treatment with desmopressin (120mcg/day). Desmopressin was increased to 240mcg/day if clinically necessary. The primary endpoint was reduction in number of wet nights, following 12 weeks of treatment with desmopressin using plasma copeptin ratio (evening/morning copeptin) at baseline. Results 18 children responded to desmopressin treatment at 12 weeks, while 9 did not. A copeptin ratio cut-off of 1.34 (sensitivity 55.56%, specificity 94.12%, AUC 70.6%, p = 0.07) was best at predicting treatment response, with a lower ratio indicating a better treatment response. In contrast, neither number of wet nights at baseline (p = 0.15), nor serum sodium (p = 0.11) alone or in combination with plasma copeptin improved outcome prediction. Conclusion Our results indicate that of our investigated parameters plasma copeptin ratio is the best predictor for treatment response in children with MNE. Plasma copeptin ratio could thus be useful to identify children with the highest benefit of desmopressin treatment and improve individualized treatment of monosymptomatic nocturnal enuresis.